Correlation Between Connect Biopharma and Protagenic Therapeutics

Can any of the company-specific risk be diversified away by investing in both Connect Biopharma and Protagenic Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Connect Biopharma and Protagenic Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Connect Biopharma Holdings and Protagenic Therapeutics, you can compare the effects of market volatilities on Connect Biopharma and Protagenic Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Connect Biopharma with a short position of Protagenic Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Connect Biopharma and Protagenic Therapeutics.

Diversification Opportunities for Connect Biopharma and Protagenic Therapeutics

-0.03

Correlation Coefficient

Connect Biopharma  Protagenic Therapeutics

Good diversification

The 3 months correlation between Connect and Protagenic is -0.03. Overlapping area represents the amount of risk that can be diversified away by holding Connect Biopharma Holdings and Protagenic Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Protagenic Therapeutics and Connect Biopharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Connect Biopharma Holdings are associated (or correlated) with Protagenic Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Protagenic Therapeutics has no effect on the direction of Connect Biopharma i.e., Connect Biopharma and Protagenic Therapeutics go up and down completely randomly.

Pair Corralation between Connect Biopharma and Protagenic Therapeutics

Given the investment horizon of 90 days Connect Biopharma Holdings is expected to generate 0.59 times more return on investment than Protagenic Therapeutics. However, Connect Biopharma Holdings is 1.68 times less risky than Protagenic Therapeutics. It trades about 0.03 of its potential returns per unit of risk. Protagenic Therapeutics is currently generating about -0.02 per unit of risk. If you would invest  123.00  in Connect Biopharma Holdings on September 13, 2024 and sell it today you would earn a total of  0.00  from holding Connect Biopharma Holdings or generate 0.0% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Connect Biopharma Holdings  vs.  Protagenic Therapeutics

Connect Biopharma

Risk-Adjusted Performance

2 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Connect Biopharma Holdings are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Connect Biopharma may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Protagenic Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Protagenic Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's forward indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Connect Biopharma and Protagenic Therapeutics

The main advantage of trading using opposite Connect Biopharma and Protagenic Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Connect Biopharma position performs unexpectedly, Protagenic Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Protagenic Therapeutics will offset losses from the drop in Protagenic Therapeutics' long position.

The idea behind Connect Biopharma Holdings and Protagenic Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.